Warner Bros. says reopening talks with Paramount on its buyout offer

Weather - Sydney 10°C

Warner Bros. says reopening talks with Paramount on its buyout offer

ECONOMY 17.02.2026

Warner Bros. says reopening talks with Paramount on its buyout offer / Photo: © AFP

Warner Bros. Discovery said Tuesday it has reopened talks with Paramount Skydance on its buyout offer, giving the company a week to beat a rival Netflix bid.

Change text size:

These discussions, scheduled to end February 23, are designed to give Paramount Skydance a chance to make its "best and final offer," Warner Bros. Discovery said in a statement that stressed it prefers the Netflix merger and has scheduled a special shareholders meeting to vote on it on March 20.

Television and film titan Warner Bros. Discovery, which owns CNN, announced in late October that it was open to acquisition offers. Its board subsequently accepted a bid from Netflix to buy only its streaming and studio business.

Paramount Skydance is seeking to buy all of Warner Bros. Discovery for $108 billion. Netflix is offering $83 billion for its more limited merger.

The Netflix offer does not include Warner Bros. Discovery's television properties such as CNN and Discovery. Those would belong to a newly created, publicly traded company called Discovery Global if the deal goes through.

Paramount Skydance accuses the Warner Bros. Discovery board of failing to present shareholders with the details needed to properly compare its offer to the Netflix bid.

During the talks that opened Tuesday, Warner Bros. Discovery said it will discuss "deficiencies that remain unresolved and clarify certain terms of PSKY's proposed merger agreement."

Paramount CEO David Ellison insists that his offer, largely financed by his father, multi-billionaire Larry Ellison, will not face the regulatory scrutiny in the US and Europe that could derail or seriously delay the Netflix deal.

With that in mind, Paramount has offered to pay Warner Bros. Discovery shareholders a "ticking fee" of 25 cents per share — roughly $650 million per quarter — for every quarter the deal is not closed beyond December 31, 2026.

Paramount has also pledged to cover the $2.8 billion termination fee owed if Warner Bros. Discovery walks away from the Netflix agreement.

Paramount's offer is fully financed by $43.6 billion in equity commitments from Larry Ellison and RedBird Capital Partners, alongside $54 billion in debt financing from Bank of America, Citigroup, and Apollo Global Management.

Critics say Netflix's acquisition of Warner Bros. would give the streaming giant too much control over Hollywood production, which is already under pressure from the streaming revolution and Netflix's lack of commitment to theatrical releases for its movies.

To address concerns about theatrical distribution, Netflix has committed to giving Warner Bros. films a 45-day theatrical window if the acquisition goes through.

A successful buyout by Paramount would see a major media property that includes CNN fall under the control of the Ellison family, which has close ties to the Trump administration.

David Ellison's recent takeover of CBS, part of the Paramount empire, has brought major editorial changes to its news coverage that are widely seen as more sympathetic to conservative criticisms of mainstream media in the United States.

Larry Ellison is also a major investor in the US operations of TikTok, at the invitation of President Donald Trump.

At a recent Senate hearing, Netflix co-CEO Ted Sarandos faced questions from Republicans about alleged political bias, telling lawmakers that "Netflix has no political agenda of any kind."

S.M.Riley--TNT

Featured

Carney touts Canada 'pivot' away from US as tariffs rise

Canadian Prime Minister Mark Carney on Tuesday said reducing economic ties with the United States would come at a cost but the long-term benefits were clear, as retaliatory tariffs on US products took effect.

The "Everlasting Battery" Inside Your Joints:UConn Professor's Self-Powered Healing Material just Got Acquired

A material that turns your own movement into medicine has just landed a corporate home. PetVivo Holdings (OTCQX: PETV), a veterinary biotech and biomedical device company focused on treating osteoarthritis in dogs and horses, has acquired PiezoBioMembrane (PBM) — a startup built around a biodegradable implant that generates electricity from the everyday force of a joint in motion, and uses that charge to help regrow cartilage from the inside out. The material is the invention of Thanh Nguyen, a professor of mechanical engineering in UConn's College of Engineering, who founded PBM in 2021 to advance new implementation methods for his work with piezoelectric materials — substances that convert mechanical force into electrical energy. These materials are typically ceramics: hard, brittle, and poorly suited for medical use. But Nguyen's lab developed new forms that are so , flexible, and biodegradable, breaking down naturally within the body over time. wound healing, The materials have already shown strong potential across a range of medical applications, including tissue regeneration, implanted force sensors, and targeted drug delivery in tumor treatment. How It Works biodegradable ultrasound for In the case of arthritis, Nguyen explains, the piezoelectric materials function as an off-the-shelf product that can be implanted or injected directly into the ailing joint — with no drugs, chemicals, or cells required. The everyday force exerted on the joint generates a small electrical charge, which helps regrow healthy cartilage, mimicking the body's natural use of electricity to regenerate tissue. "The body can be electrically stimulated to regrow," Nguyen says. PBM's materials "act like a battery — an everlasting battery that works whenever there is a force applied, and vanishes safely inside the body over time." PetVivo's Vision for the Acquisition PetVivo Holdings CEO John Lai expressed enthusiasm for the merger's potential to improve the lives of companion animals globally. "PBM has developed a compelling functional biomaterials platform with the potential to support the development of multiple medical device and therapeutic product lines across both human and animal health markets," Lai said in a press release. "By combining PBM's scientific innovation with PetVivo's product development capabilities, commercialization experience, regulatory expertise, and public company infrastructure, we believe we can accelerate theadvancement of technologies that may serve as the foundation for numerous future products and strategic opportunities." For Nguyen, the deal is a chance to scale technology that could eventually benefit both animals and people. "PetVivo is an animal health company, but they do have a big passion: pushing the technology towards clinical trials for human use," Nguyen says. "That aligned perfectly with my passion for developing technology that has an impact on human life. That is why I am excited about this merger, which facilitates my passion." A Track Record of Innovation Nguyen's research sits at the intersection of medicine, micro/nanotechnology, and biomaterials. His inventions have earned him publications in prominent scientific journals and media coverage from outlets including NPR. Nguyen founded PBM during the COVID-19 pandemic, a er realizing the material he had developed could be used to create an especially effective, biodegradable face mask — one where the mechanical force of breathing generated an electrical charge that provided an extra layer of protection against viruses. PBM is not Nguyen's only venture in the acquisition pipeline. His other startup, Single-Time Microneedles (STM), is also currently undergoing an acquisition process. STM has pioneered stable, efficient vaccine delivery technology in the form of an adhesive patch. shelfNguyen's focus on biodegradable materials has translated into a remarkably diverse range of medical applications. He has received five R01 grants from the National Institutes of Health (NIH) supporting research in cartilage regeneration, bone regeneration, HIV antibody delivery systems, and biodegradable ultrasound technology to boost the effectiveness of chemotherapy for brain cancer. "Whatever we are working on, we want to show that it works very well in vitro and in vivo," Nguyen says. "Then, when we are at the point of commercialization, we set up a startup or license the technology — or maybe team up with an industry partner." Thanh Nguyen is a professor of mechanical engineering in UConn's College of Engineering. (Courtesy of Thanh Nguyen

Octrado introduces its proprietary trading offering: "Your Skill. Our Capital"

Infrastructure, transparent rules and clear legal boundaries positioned as the core of the funded-account model

Could gas prices return to 2022 highs on US-Iran war?

European gas prices have more than doubled owing to the US-Iran war, just as Europe needs to replenish its reserves ahead of winter.

Change text size:

The National Times - Warner Bros. says reopening talks with Paramount on its buyout offer